Skip to main content

Chronic Pancreatitis

Gastroenterology
3
Pipeline Programs
15
Companies
12
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 14 programs with unclassified modality

Gastroenterology is a $7.3B market characterized by mature, blockbuster-driven portfolios with near-term patent cliff risks.

$7.3B marketMature→ Stable30 products15 companies

Key Trends

  • AbbVie dominance with 43% of top-10 product spending (LINZESS, CREON, RINVOQ)
  • Guanylate cyclase activators and JAK inhibitors driving innovation in constipation and IBD
  • Multiple patent expirations 2026–2030 creating biosimilar and generic erosion headwinds

Career Verdict

Gastroenterology offers stable, well-compensated roles but limited growth upside; best for risk-averse professionals seeking established markets over innovation-driven career trajectories.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1LINZESSStable
$1.8B
AbbVie·Peak7.7yr
#2CREONDeclining
$1.5B
AbbVie·LOE Approaching
#3XIFAXANDeclining
$1.1B
Bausch Health·LOE Approaching
#4RINVOQGrowing
$976M
AbbVie·Peak11.8yr
#5XELJANZ XRStable
$586M
Pfizer·Peak8.3yr

Drug Class Breakdown

Unknown Mechanism
$2.5B(34%)

mature portfolio anchor

Guanylate Cyclase Activators
$1.9B(27%)

well-established class

Pancreatic Enzymes
$1.5B(20%)

facing biosimilar competition

Janus Kinase Inhibitors
$976M(13%)

growing IBD adoption

Proton Pump Inhibitors
$107M(1%)

commoditized

Career Outlook

Stable

Gastroenterology is a stable, mature market anchored by blockbusters with long patent runways (LINZESS to 2034, RINVOQ to 2038) but faces near-term erosion (XELJANZ 2026). Employment growth is modest and concentrated in device/diagnostic firms rather than pure-pharma. Best for professionals seeking predictable revenue streams over high-risk innovation bets.

Breaking In

Target roles at Roche, J&J, or diagnostic-adjacent firms to maximize hiring volume; pure pharma gastro entry points at AbbVie/Pfizer are limited and highly competitive.

For Experienced Professionals

Leverage gastro expertise in broader GI/immunology roles (Takeda, Novartis) or transition to medical devices/diagnostics where hiring is 3x higher than pharma.

In-Demand Skills

IBD and IBS indication expertiseJAK inhibitor pharmacologyMedical device integration (diagnostics, endoscopy)Generic/biosimilar launch readinessReal-world evidence generation

Best For

Medical Science Liaison (IBD/IBS focus)Commercial Manager (Generic Launch)Clinical Operations SpecialistMarket Access/Reimbursement StrategistRegulatory Affairs (small molecule focus)

Hiring Landscape

$70K-$213K

Total hiring across the gastro ecosystem is 1,818 jobs, dominated by engineering (434) and commercial roles (269). Roche leads absolute hiring at 377 roles, followed by Johnson & Johnson (323) and GE HealthCare (293), reflecting broad medical device and diagnostic involvement alongside pharma. AbbVie's gastro-specific hiring (78 jobs) is modest relative to its portfolio dominance.

1,818
Open Roles
4
Companies Hiring
3
Departments

Top Hiring Companies

377Growing
293Stable
78Stable

By Department

Engineering(24%)
$169K
Commercial(15%)
$176K
Manufacturing(10%)
$213K

Manufacturing and commercial roles command premium salaries ($213K and $176K respectively), but total gastro-pharma hiring is concentrated in Roche and J&J, not pure-play GI companies.

Competitive Landscape

13 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
Creon36™Phase 21 trial
CREONN/A1 trial
Active Trials
NCT04949828Completed63Est. Feb 2024
NCT02849704Completed48Est. Nov 2017
Pfizer
PfizerNEW YORK, NY
1 program
1
TanezumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT01146561Terminated2Est. Mar 2011
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
NexiumPhase 11 trial
Active Trials
NCT01142128Terminated12Est. Mar 2012
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
CarePrep Online Health AssessmentN/A1 trial
Web-based CBTN/A
Active Trials
NCT02122302Withdrawn0Est. May 2016
Medtronic
MedtronicNJ - Phillipsburg
1 program
Closed Loop InsulinN/A1 trial
Active Trials
NCT01945138Completed14Est. Dec 2015
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
Ivacaftor 150 MGN/A1 trial
Active Trials
NCT07022327Active Not Recruiting1Est. Aug 2026
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
PANQOLIN/A1 trial
Active Trials
NCT03632616Enrolling By Invitation500Est. Aug 2026
Boston Scientific
Boston ScientificCA - Valencia
1 program
Pancreatic fully-covered self-expanding metal stentN/A1 trial
Active Trials
NCT02802020Completed67Est. Nov 2021
Eppendorf
EppendorfGermany - Hamburg
1 program
Robot-assisted lateral pancreaticojejunostomyN/A1 trial
Active Trials
NCT07109180Recruiting28Est. Dec 2026
Ariel Precision Medicine
1 program
Web-based CBTN/A1 trial
Active Trials
NCT03707431Completed90Est. Jul 2024
Utah Medical
Utah MedicalIreland - Dublin
1 program
Web-based CBTN/A
Precision BioSciences
1 program
Web-based CBTN/A
Bristol Myers Squibb
1 program
ThalidomidePHASE_21 trial
Active Trials
NCT00469703Terminated10Est. Nov 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieCreon36™
PfizerTanezumab
Bristol Myers SquibbThalidomide
AstraZenecaNexium
Mission TherapeuticsIvacaftor 150 MG
EppendorfRobot-assisted lateral pancreaticojejunostomy
AbbVieCREON
Ariel Precision MedicineWeb-based CBT
Colorado TherapeuticsPANQOLI
Boston ScientificPancreatic fully-covered self-expanding metal stent
Angeles TherapeuticsCarePrep Online Health Assessment
MedtronicClosed Loop Insulin

Clinical Trials (12)

Total enrollment: 835 patients across 12 trials

Fat Malabsorption in Chronic Pancreatitis

Start: Oct 2016Est. completion: Nov 201748 patients
Phase 2Completed

Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis

Start: Oct 2010Est. completion: Mar 20112 patients
Phase 2Terminated

Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis

Start: Aug 2005Est. completion: Nov 200710 patients
Phase 2Terminated

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

Start: Feb 2009Est. completion: Mar 201212 patients
Phase 1Terminated

Ivacaftor Impact in an Adolescent Without a Cystic Fibrosis-Associated CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Mutation for Chronic Pancreatitis: Single-Patient Study Tracking Flare Frequency and Health Data Compared to Historical Records.

Start: May 2025Est. completion: Aug 20261 patients
N/AActive Not Recruiting
NCT07109180EppendorfRobot-assisted lateral pancreaticojejunostomy

Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOTTA)

Start: Apr 2025Est. completion: Dec 202628 patients
N/ARecruiting

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

Start: Sep 2021Est. completion: Feb 202463 patients
N/ACompleted

Internet Based Cognitive Behavioral Therapy in Pediatric Chronic Pancreatitis

Start: Apr 2019Est. completion: Jul 202490 patients
N/ACompleted

Quality of Life Assessment of Chronic Pancreatitis Endoscopic Interventions

Start: Jul 2017Est. completion: Aug 2026500 patients
N/AEnrolling By Invitation
NCT02802020Boston ScientificPancreatic fully-covered self-expanding metal stent

WallFlex Pancreatic Metal Stent for Pancreatic Duct Strictures

Start: Jan 2017Est. completion: Nov 202167 patients
N/ACompleted
NCT02122302Angeles TherapeuticsCarePrep Online Health Assessment

Online Health Assessment to Support Comprehensive Care

Start: May 2014Est. completion: May 20160
N/AWithdrawn
NCT01945138MedtronicClosed Loop Insulin

Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation

Start: Feb 2014Est. completion: Dec 201514 patients
N/ACompleted

Related Jobs in Gastroenterology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 835 patients
15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.